When AI Designs a Drug, Who Gets the Credit?

When an AI system designs a new drug, who deserves the credit? This is the complex question at the heart of a recent article from MIT Technology Review, which examines the case of Insilico Medicine and its claim that its generative AI platform 'discovered' a promising drug for pulmonary fibrosis. The case is a fascinating look at the changing nature of scientific innovation. Insilico's AI was able to identify a novel target and generate a candidate molecule in a fraction of the time it would take traditional methods. The company has celebrated this as a triumph of AI-driven discovery, positioning the technology as the primary inventor. However, the reality is far more nuanced. The AI did not work in a vacuum. It was trained on vast datasets curated by human scientists, and its algorithms were designed and refined by a team of researchers. The drug candidate it produced still required extensive human-led testing and validation to ensure it was safe and effective. The question of credit is not just academic; it has profound implications for intellectual property law and scientific attribution. If an AI is considered the inventor, then who owns the patent? Current laws are ill-equipped to handle this scenario, as they typically require a human inventor. This creates a legal gray area that could stifle innovation if not addressed. Companies like Insilico are pushing for new frameworks that recognize the collaborative nature of AI-driven research, where both the human engineers and the AI system play crucial roles. The article argues that we need to move beyond the simplistic notion of a single 'inventor.' Instead, we should think of AI as a powerful tool that amplifies human creativity. The human researchers who define the problem, design the experiments, and interpret the results are still essential. The AI is a partner, not a replacement. This shift in perspective has practical consequences. It affects how credit is assigned in academic papers, how royalties are distributed, and how regulatory bodies evaluate new drugs. The MIT Technology Review piece highlights the urgent need for new legal and ethical frameworks that can keep pace with technological advancements. Without them, we risk creating a system that either undervalues the contribution of human researchers or fails to properly incentivize the use of AI in drug discovery, ultimately slowing down the development of life-saving treatments.